Pharmaceutical Research Unit (PRU) is pleased to announce the renewal of its accreditation with the National Pharmaceutical Regulatory Agency (NPRA). This extension confirms PRU’s certification until 6 July 2025, reinforcing its commitment to high-quality standards in the clinical trials industry.

Established in 1993, PRU is a leader in bioequivalence studies, offering services such as clinical trials setup, bioanalysis, and data management. The renewed NPRA accreditation underscores PRU’s dedication to regulatory compliance and excellence.

We are thrilled to announce that Arab Pharmaceutical Industry Consulting and PRU has successfully renewed its GCC accreditation. This prestigious achievement underscores our unwavering commitment to excellence and our dedication to maintaining the highest standards in the pharmaceutical industry.